About 10% of acute hepatitis cases and 50% of acute liver failure are caused by drug induction, where treatment remains largely limited. The SLIT/ROBO signaling axis is composed of the secretory SLIT ...

Biolexis Therapeutics Inc. has identified AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of diabetes, ischemia-reperfusion injury, dyslipidemia, obesity, ...

Medulloblastoma is one of the most common pediatric brain malignancies. A deeper understanding of the mechanisms underlying ...

Pulmonary fibrosis is a chronic, progressive respiratory disease in which the normal barrier between alveoli and capillaries is compromised, leading to persistent injury and inflammation of the lung ...

Ebola virus (EBOV) causes severe febrile illness that frequently leads to death within 10 days of infection due to multiorgan failure. Different therapeutic strategies have been developed against EBOV ...

Shanghai Henlius Biotech Inc. has entered into an exclusive global license agreement with U-mab Biopharma (Lianyungang) Co. Ltd., securing rights to a monoclonal antibody (mAb) targeting interleukin-1 ...

Distalmotion SA recently secured a strategic investment from Johnson & Johnson for its robotic-assisted surgical system Dexter, amid an increase in demand from ambulatory surgery centers for such ...

Neurocrine Biosciences Inc. has disclosed chemically modified polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor (GCGR) and/or glucagon-like peptide 1 ...

The EMA had its second busiest year ever in 2025, approving 104 drugs, of which 38 had a new active substance. Sixteen of ...

Chengdu Zeling Biomedical Technology Co. Ltd. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic ...

Biopharma financing values have shown quarterly volatility over the past decade, with surges often concentrated in specific quarters rather than evenly distributed throughout the year. The pandemic ...

Neuroplastogens are an emerging class of compounds that promote neuroplasticity in the brain without inducing hallucinogenic effects. Transneural Therapeutics Inc. has presented data regarding their ...